Key result
Ranolazine treatment resulted in a significant reduction in ventricular tachycardia and no ICD shocks in 92% of patients with antiarrhythmic-drug-refractory VT over a 6-month follow-up.
Why the study?
Does ranolazine reduce VT burden and ICD shocks in patients with AAD-refractory VT?
Observational (n=12)
Does ranolazine reduce VT burden and ICD shocks in patients with AAD-refractory VT?
Ranolazine effectively reduced VT burden and eliminated ICD shocks in a small cohort of patients with AAD-refractory VT.
No takes yet. Share an insight, caveat, or question.
May support ranolazine in AAD-refractory VT; leaves open confirmation in randomized trials.
Bunch et al. (2011) conducted an observational in Antiarrhythmic-drug-refractory ventricular tachycardia with recurrent ICD shocks (n=12). Ranolazine was evaluated on Reduction in VT and ICD shocks. Ranolazine treatment resulted in a significant reduction in ventricular tachycardia and no ICD shocks in 92% of patients with antiarrhythmic-drug-refractory VT over a 6-month follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: